The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Eversense 365, the world’s first 365-day CGM system, is the only CGM offering a year-long wear time. Market-leading, ...

G6 continuous glucose monitor (CGM) receivers deliver glucose readings and alerts. However, certain devices may experience an ...

Dexcom bet on the high financial ceiling that exists by integrating its glucose monitoring capabilities into the ring, culminating in a $75m investment in Ō ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

DexCom (NASDAQ: DXCM) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels. However, the rising popularity of GLP-1 drugs ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A better-than-expected third-quarter 2024 performance and a series of favorable coverage ...

Redburn Atlantic upgraded DexCom (DXCM) to Buy from Neutral with a price target of $115, up from $85. The company is positioned to benefit from ...

DXCM data by YCharts. There are excellent reasons to think DexCom can continue riding the CGM wave. Let's consider three. First, the CGM market for diabetes patients remains underpenetrated even ...